SymBio has substantially increased the value of its Treakisym franchise through in-licensing novel bendamustine formulations from Eagle Pharmaceuticals for $12.5m. The new formulations bring a lower cost of goods and 10 years of additional patent protection to help in life cycle management of the Treakisym franchise. Sales of Treakisym following the approval of two new indications in 2016 have exceeded the company’s expectations, leading it to upgrade FY17 sales guidance. Interim data f
02 Nov 2017
SymBio Pharmaceuticals - New formulations extend Treakisym patent life
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SymBio Pharmaceuticals - New formulations extend Treakisym patent life
Symbio Pharmaceuticals Limited (4582:TKS) | 0 0 0.0%
- Published:
02 Nov 2017 -
Author:
Dr Dennis Hulme -
Pages:
10
SymBio has substantially increased the value of its Treakisym franchise through in-licensing novel bendamustine formulations from Eagle Pharmaceuticals for $12.5m. The new formulations bring a lower cost of goods and 10 years of additional patent protection to help in life cycle management of the Treakisym franchise. Sales of Treakisym following the approval of two new indications in 2016 have exceeded the company’s expectations, leading it to upgrade FY17 sales guidance. Interim data f